This milestone came with an asterisk.

(Bloomberg) -- The Trump administration’s fitful campaign to address US voters’ affordability concerns ahead of the midterm elections is faltering, with some key efforts stalled, cast aside or limited in scope. Most Read from BloombergUS Has Opened a Passage Through Hormuz, Central Command SaysDOJ Plans Intervention in Trump Supreme Court Carroll AppealBillionaire Duke of Westminster to Sell £700 Million of US Real Estate AssetsChina Asks Banks to Pause New Loans to US-Sanctioned RefinerSony to

Ultragenyx posts a wider-than-expected Q1 loss as Crysvita sales fall on seasonal effects, while Evkeeza and Dojolvi revenue growth partially offset declines.

New clinical data reinforce Dupixent’s role in treating eosinophilic esophagitis and may support its long-term positioning in the indication. Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is seeing a modest reset in fair value estimates, with one updated model lifting the figure slightly to US$875.31 from US$873.78. That small move lines up with a broader mix of analyst reactions, where some are raising targets on confidence in Dupixent and the pipeline, while others trim expectations on Eylea, competition and execution risk. As you read on, you will see how these shifting price targets fit into the evolving story and what signals to watch...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most profitable biotech stocks to buy now. On April 10, Piper Sandler reaffirmed an Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with a $875 price target. The assessment followed an Integrated Oncology Day event at the Sylvester Cancer Center in Miami. The event included discussions on oncology therapies […]

Regeneron is seeing double-digit revenue growth and has more than 50 therapies in its pipeline, making it a good long-term investment.

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.

Regeneron Pharmaceuticals' (REGN) Q1 results reflected mixed trends, as weaker-than-expected sales o